Based on this decision by the FDA, Lilly has gained an additional six months of U.S. market exclusivity for Cymbalta, which now will expire in The approval of pediatric exclusivity does not mean that Cymbalta is approved for use in pediatric patients.
URL: http://www.topix.com/health/depression/2012/07/lilly-obtains-six-months-u-s-pediatric-exclusivity-for-cymbalta?fromrss=1
No comments:
Post a Comment